The company is set to introduce multi-omics capabilities on the AVITI platform, along with enhancements to the first commercial Q50 kit and a host of workflow improvements, all slated for release this year.

The flagship product, AVITI, experienced an extraordinary reception throughout 2023, as highlighted by remarkable achievements:

• Over 160 Commercial Orders: AVITI surpassed expectations, securing over 160 commercial orders, with a significant milestone achieved in September 2023 when orders exceeded 100.

• Expanded Installed Base: AVITI's installed base reached 112 instruments, a testament to its widespread adoption and trust among research institutions and laboratories.

• $25 Million in Revenue: Element Biosciences reported substantial revenue generation, surpassing $25 million, underscoring AVITI's robust position in the market.

Molly He, CEO of Element Biosciences, expressed her enthusiasm, stating, "When we launched AVITI in 2022, we redefined the possibilities of benchtop sequencers, offering an unparalleled combination of accuracy, speed, and cost-effectiveness. Today, we are once again raising the industry bar. These advancements mean that scientists worldwide will spend less time on resource planning and more time analyzing meaningful data, with the potential to profoundly impact our lives."

Element Biosciences remains committed to pushing the boundaries of genomics technology, empowering researchers globally, and fostering collaborative efforts to shape the future of scientific discovery.